Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, CRMO, Still's Disease, Behcet's Disease, and Other Undifferentiated Autoinflammatory Diseases)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) )
ClinicalTrials.gov Identifier:
NCT00059748
First received: May 5, 2003
Last updated: November 11, 2014
Last verified: July 2014
  Purpose

Background:

- Autoinflammatory diseases can cause fevers, rashes, joint and nerve problems, ulcers, and many other problems. Researchers want to study people with these diseases and their relatives to learn more about the diseases.

Objectives:

- To study the signs and symptoms of autoinflammatory diseases and find out why they cause inflammation.

To find things in blood, body fluids, and genes that cause these diseases. To collect information about people with these diseases.

Eligibility:

  • People with NOMID/CAPS, DIRA, CANDLE, SAVI, CRMO, Still's Disease, Behcet's Disease, and other undifferentiated autoinflammatory diseases.
  • Healthy relatives.

Design:

  • Participants will stay at or near the clinic for 3 5 days or more.
  • All participants will have medical history, physical exam, and blood tests.
  • Participants may have:
  • Questions about their quality of life.
  • Fluid taken by needle from a swollen joint.
  • Tests of eyes, hearing, memory, and learning.
  • Urine test.
  • Questions about their symptoms.
  • Small samples of skin taken.
  • X-rays, CT scans, or MRI. For MRI, participants will lie still on a table in a metal cylinder for 45 minutes. The scanner makes loud knocking sounds. Participants will get earplugs. Some participants will have a contrast agent injected.
  • Bone density scan. They will lie still for 5 minutes while pictures are taken.
  • Coordination test.
  • Fluid taken by needle from the spine.
  • Pictures taken in a bathing suit or underwear.
  • Gastrointestinal tests. Participants will drink a special solution. Then a tiny camera will go inside the body on a tube, or taken in a pill.
  • Participants may return for follow-up visits.

Condition
Urticaria
Arthropathy
Lymphadenopathy
Nervous System Anomalies

Study Type: Observational
Official Title: Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, CRMO, Still s Disease, Behcet s Disease, and Other Undifferentiated Autoinflammatory Diseases)

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 99999999
Study Start Date: April 2003
Detailed Description:

Autoinflammatory multisystem diseases are a group of diseases that are characterized by recurrent episodes of systemic inflammation as well as organ specific inflammation that can involve the skin, eyes, joints, bones, serosal surfaces, inner ear, and brain. The prominent role of IL-1 in the pathogenesis of these disorders has first become evident through the discovery of mutations in CIAS1 causing the cryopyrin-associated periodic syndromes (CAPS) including the most severe presentation Neonatal Onset Multisystem Inflammatory Disease (NOMID). We recently identified a new autoinflammatory disease DIRA (Deficiency of IL-1 Receptor Antagonist), a disease that is caused by mutations in IL1RN. Therapy with anakinra, the IL-1 receptor antagonist, can be life-saving. We also study additional rare diseases including CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures), the spectrum CRMO (Chronic Recurrent Multifocal Osteomyelitis), Still s disease, and Beh(SqrRoot)(Beta)et s disease (BD) all of which may involve dysregulation of IL-1. In this research protocol we seek to comprehensively evaluate affected patients clinically, genetically, immunologically, and endocrinologically. In addition we intend to evaluate long term outcome and biomarkers. Eligibility for ongoing and planned treatment protocols will be determined by screening patients in this protocol. We plan to evaluate patients on a consultative basis for other autoinflammatory diseases for possible enrollment into this study.

  Eligibility

Ages Eligible for Study:   3 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:

Subjects with known or suspected diagnosis of NOMID/CAPS, DIRA, CRMO, Still's disease, Behcet's disease, and other autoinflammatory diseases will be evaluated either at the outpatient or inpatient unit of the Clinical Center as indicated.

  • Patients with NOMID/CAPS or DIRA, who are mutation positive for the disease or fulfill clinical criteria of the disease.
  • Patients who have non infectious osteolytic bone lesions
  • Patients who fulfill criteria for definite or probable Still's disease
  • Patients who fulfill criteria for definite or probable Behcet's disease
  • Patients with other suspected autoinflammatory diseases

There is:

  • No age limit
  • Patients or their legal guardians need to be able and willing to give informed consent and a pediatric patient needs to be willing to assent.

Relatives of patients with autoinflammatory diseases or healthy volunteers may be included for genetic testing in collaboration with Dr. Daniel Kastner's laboratory. We may also collect blood for serum and RNA analyses to establish a cohort of healthy controls that is matched in age, gender, and ethnicity to the study patients.

EXCLUSION CRITERIA:

Active malignancy or any medical condition that in the opinion of the investigator would warrant exclusion

Inability to provide consent

Inability to return for follow up visits

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00059748

Contacts
Contact: Michelle O'Brien, R.N. (301) 496-2237 obrienm@mail.nih.gov
Contact: Raphaela T Goldbach-Mansky, M.D. (301) 435-6243 goldbacr@mail.nih.gov

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)    800-411-1222 ext TTY8664111010    prpl@mail.cc.nih.gov   
Sponsors and Collaborators
Investigators
Principal Investigator: Raphaela T Goldbach-Mansky, M.D. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  More Information

Additional Information:
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: National Institutes of Health Clinical Center (CC) ( National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) )
ClinicalTrials.gov Identifier: NCT00059748     History of Changes
Other Study ID Numbers: 030173, 03-AR-0173
Study First Received: May 5, 2003
Last Updated: November 11, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Central Nervous System Abnormalities
Arthropathy
Urticaria
Papilledema
Autoinflammation
Neonatal Onset Multisystem Imflammatory
Disease
NOMID

Additional relevant MeSH terms:
Urticaria
Joint Diseases
Nervous System Malformations
Congenital Abnormalities
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Musculoskeletal Diseases
Nervous System Diseases
Skin Diseases
Skin Diseases, Vascular

ClinicalTrials.gov processed this record on November 20, 2014